<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-949
Date of Submission: 2025-01-18

This report was submitted by a Pharmacist from Strickland, Kelly and Watson Medical Center concerning patient ANON-PX-2689. The subject is a 74-year-old male with a significant medical history including chronic kidney disease, type 2 diabetes, osteoarthritis, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Oral route at a dosage of 263mg, initiated on 2024-11-25 for Thromboembolism prevention and discontinued on 2025-01-09; Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 94mg, initiated on 2024-11-25 for Neuropathic pain and discontinued on 2025-01-09.

On approximately 2024-12-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Stevens-Johnson syndrome. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Similar either purpose now available have. Nor local human since number indicate head. No his customer arm affect.</data>
report_id: ADR-2025-949
report_date: '2025-01-18'
patient_details:
  patient_id: ANON-PX-2689
  gender: Male
  relevant_history:
  - chronic kidney disease
  - type 2 diabetes
  - osteoarthritis
  - hypertension
  age_at_reaction: 74
suspected_drugs:
- drug_name: Warfarin
  dosage: 263mg
  route_of_administration: Oral
  start_date: '2024-11-25'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2025-01-09'
- drug_name: Gabapentin
  dosage: 94mg
  route_of_administration: Oral
  start_date: '2024-11-25'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-01-09'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2024-12-03'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-12-03'
  severity: Mild
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
reporting_facility: Strickland, Kelly and Watson Medical Center
reporter_type: Pharmacist
notes: Similar either purpose now available have. Nor local human since number indicate
  head. No his customer arm affect.
